Kymab and LifeArc enter strategic partnership to discover new medicines using Kymab’s IntelliSelect® technologies

Cambridge, UK: June 24, 2019: Kymab, a clinical-stage biopharmaceutical company developing antibody-based therapeutics, today announced a strategic partnership agreement with LifeArc, a leading UK medical research charity. The agreement will enable LifeArc to enhance its antibody drug discovery capabilities into new medicinal products with Kymab’s proprietary IntelliSelect technology platforms.